Immupharma (IMM)

 

IMM Share PerformanceMore

52 week high193.000 04/01/18
52 week low19.000 17/04/18
52 week change -26.400 (-48.89%)
4 week volume55,454,818 29/04/18
price27.600
price date1527265429
close28.700

Latest NewsMore

Most popular FTSE 100, AIM and overseas shares in April 2018

In one of the best months for equity markets in the past decade, Lee Wild reveals which blue chip, AIM and international ...

Holding(s) in Company

RNS Number: 9492L Immupharma PLC 24 April 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Immupharma plc 1b...

Holding(s) in Company

RNS Number: 5795L Immupharma PLC 20 April 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Immupharma plc 1b...

Holding(s) in Company

RNS Number: 4403L Immupharma PLC 19 April 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Immupharma plc 1b...

FTSE follows US higher

The FTSE 100 was lifted by a raft of positive financial results and a strong performance in the US overnight, helping the b...

ImmuPharma's Lupuzor fails to meet primary endpoint in phase III trial

ImmuPharma said Tuesday its pivotal Phase III trial of lupus treatment Lupuzor failed to meet the trial's primary endpoin...

Topline results of Lupuzor Pivotal Phase III Trial

RNS Number: 0988L Immupharma PLC 17 April 2018 17 April 2018 This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ImmuPharma PLC ("ImmuPharma" or the "Company") Topline results of Lupuzor Pivotal Phase III Trial ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development comp...

Appointment of Joint Broker

RNS Number: 1578J Immupharma PLC 28 March 2018 28 March 2018 ImmuPharma PLC ("ImmuPharma" or the "Company") Appointment of Joint Broker ImmuPharma PLC (AIM: IMM.L) , the specialist drug discovery and development company, is pleased to announce that it has with immediate effect appointed Bryan, Garnier & Co. Limited as its joint corpora...

Fundamental DataMore

EPS-4.54
Dividend yield0 %

Latest discussion posts More

  • Next leg up

    Reckon these will settle around 40-45p by the end of the week
    1-May-2018
    zombynation
  • Cheap

    Price back to attractive level. Topped up today. Lack of news is dragging the price down.
    1-May-2018
    bestone
  • price drop

    big drop today maybe should get out any suggestions
    27-Apr-2018
    DIE HARD 1

Users' HoldingsMore

Users who hold Immupharma also hold..

Codes & Symbols

ISINGB0033711010
SymbolsIMM, LSE:IMM, IMM.L, IMM:LN, LON:IMM, XLON:IMM